INCY Q3 deep dive: product diversification accelerates as R&D spending weighs on margins

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 14% year on year to $1.56 billion. On the other hand, the company’s full-year revenue guidance of $5.26 billion at the midpoint came in 11.3% below analysts’ estimates. Its non-GAAP loss of $3.60 per share was 6.9% above analysts’ consensus estimates.

Is now the time to buy INCY? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Incyte’s third quarter results reflected continued revenue momentum, supported by broad-based growth across its product portfolio, especially the expansion of its core business beyond Jakafi. Management attributed the quarter’s performance to strong demand for OPZELURA and hematology-oncology brands, alongside increased adoption in both U.S. and international markets. CEO Bill Meury highlighted that every product posted year-over-year growth, and emphasized that “sales from our core business, excluding Jakafi, increased 30% from prior year.” The company also noted that strategic investments in commercial execution and expanded sales efforts helped drive prescription growth, particularly in dermatology. However, the quarter’s operating margin was pressured by a substantial in-process R&D charge related to the Vega Therapeutics acquisition, which management called out as a key driver of higher expenses.

Looking forward, Incyte’s updated guidance is based on management’s expectation for sustained momentum in its late-stage pipeline and ongoing market penetration for OPZELURA and other core products. CFO Suky Upadhyay stated that elevated R&D and SG&A spending will continue as the company invests in pivotal trials and pre-launch activities for potential new indications, particularly in hematology and dermatology. Management also stressed that regulatory decisions and clinical trial readouts—such as those for povorcitinib and several phase III oncology assets—will be pivotal signposts for future growth. While leadership expressed confidence in the company’s ability to meet its growth objectives, they acknowledged that execution on late-stage development and successful product launches will be essential to achieving long-term targets.

Key insights from management’s remarks

Management credited the quarter’s revenue growth to increased demand for OPZELURA and robust expansion in hematology-oncology, while emphasizing the impact of pipeline progress and regulatory milestones as the company transitions beyond Jakafi.

• OPZELURA’s prescription momentum: The dermatology franchise, led by OPZELURA, benefited from expanded sales force, increased promotion, and broader formulary coverage. Management noted strong prescription demand and new patient starts, with U.S. net sales up 45% year-over-year, supported by strategic investments in commercial access.

• Hematology-oncology growth drivers: The core business excluding Jakafi saw 30% year-over-year sales growth, fueled by key brands such as NIKTIMVO, ZYNYZ, and MONJUVI. Management noted these brands are on track to contribute significantly to the company’s revenue diversification strategy by 2030.

• Pipeline advancement and regulatory milestones: Multiple late-stage pipeline assets advanced, including approvals and launches for OPZELURA in the EU and NDA reviews for MONJUVI and povorcitinib. The acquisition of Vega Therapeutics brought a novel Protein S modulator into phase III, further expanding the hematology pipeline.

• Portfolio prioritization and trial decisions: Incyte adjusted its oncology strategy by deprioritizing development in platinum-resistant ovarian cancer for its CDK2 inhibitor due to challenging enrollment and competitive landscape, while focusing resources on high-potential programs such as G12D and TGFβ×PD-1 bispecific antibody trials.

• R&D and M&A impact on margins: The Vega acquisition led to a significant in-process R&D charge, inflating expenses and driving the sharp decline in operating margin. Management reiterated that disciplined investment in late-stage programs and targeted M&A are essential for long-term growth, despite near-term pressure on profitability.

Drivers of future performance

Incyte’s outlook is shaped by continued investment in late-stage trials, key regulatory decisions, and the scaling of recently launched and pipeline products.

• Late-stage pipeline execution: Management emphasized that advancing six phase III assets—spanning hematology, oncology, and dermatology—will be critical to sustaining post-2029 growth. Clinical trial enrollment, regulatory milestones, and timely data readouts are positioned as top priorities, with leadership highlighting that “if we deliver against them, we believe the value creation potential is substantial.”

• Product launches and label expansions: Forthcoming regulatory decisions on povorcitinib and MONJUVI, along with potential new indications for OPZELURA, represent opportunities to increase the company’s addressable market. Success in obtaining broader labels, especially for povorcitinib in hidradenitis suppurativa (HS), is expected to drive incremental revenue and market share.

• Expense management and R&D investment: Elevated R&D and SG&A expenses will persist as Incyte funds pivotal trials and commercial launches. Management cautioned that while these investments are necessary for future growth, they will continue to pressure margins in the near term, making operational discipline and prioritization of high-potential programs essential.

Catalysts in upcoming quarters

Looking forward, StockStory analysts will focus on (1) clinical data updates and regulatory milestones for pivotal pipeline assets such as INCA033989, povorcitinib, and MONJUVI; (2) signs of sustained growth in OPZELURA’s market penetration, including in new indications and international expansion; and (3) progress in integrating the Vega Therapeutics acquisition and the advancement of its Protein S modulator in clinical trials. Ongoing expense trends and margin recovery will also be key areas of attention.

Incyte currently trades at $120.37, up from $116.87 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Stocks that trumped tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.